Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy.

[1]  K. Goa,et al.  Tranexamic Acid , 1999, Drugs.

[2]  J. Bernstein,et al.  Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. , 2010, The New England journal of medicine.

[3]  A. Sheffer,et al.  Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.

[4]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[5]  M. Cicardi,et al.  The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. , 2010, Current molecular medicine.

[6]  Francesco Tedesco,et al.  Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. , 2009, The Journal of allergy and clinical immunology.

[7]  J. Cesbron,et al.  Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  A. Kaplan,et al.  Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. , 2009, Journal of Allergy and Clinical Immunology.

[9]  K. Bork,et al.  Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. , 2009, The Journal of allergy and clinical immunology.

[10]  T. Craig,et al.  When is prophylaxis for hereditary angioedema necessary? , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  Q. Duan,et al.  Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. , 2009, The Journal of allergy and clinical immunology.

[12]  M. Cicardi,et al.  C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. , 2009, Trends in molecular medicine.

[13]  T. Craig,et al.  Treatment of hereditary angioedema: current perspectives. , 2008, Recent patents on inflammation & allergy drug discovery.

[14]  A. Kaplan,et al.  Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. , 2008, Annals of Allergy, Asthma & Immunology.

[15]  A. Tordai,et al.  Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. , 2008, Molecular immunology.

[16]  M. Frank.  8. Hereditary angioedema. , 2008, The Journal of allergy and clinical immunology.

[17]  M. Frank.  Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  William H. Yang,et al.  Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  B. Zuraw.  Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  J. Bernstein.  Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  Lynda Schneider,et al.  Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. , 2007, The Journal of allergy and clinical immunology.

[22]  P. Schlattmann,et al.  Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.

[23]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[24]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[25]  A. Kaplan,et al.  Continuing Medical EducationAngioedema , 2005 .

[26]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[27]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[28]  K. Bork,et al.  Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. , 2003, Journal of the American Dental Association.

[29]  M. Cicardi,et al.  Bradykinin and the pathophysiology of angioedema. , 2003, International immunopharmacology.

[30]  M. Silverberg,et al.  Pathways for bradykinin formation and inflammatory disease. , 2002, The Journal of allergy and clinical immunology.

[31]  A. Kaplan,et al.  Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.

[33]  J. Whisstock,et al.  The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins , 2001, The Journal of Biological Chemistry.

[34]  A. Kaplan,et al.  Factor XII-dependent Contact Activation on Endothelial Cells and Binding Proteins gC1qR and Cytokeratin 1 , 2001, Thrombosis and Haemostasis.

[35]  R. Read,et al.  Structure of a serpin–protease complex shows inhibition by deformation , 2000, Nature.

[36]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[37]  A. Davis,et al.  Regulation of C1 inhibitor synthesis. , 1998, Immunobiology.

[38]  A. Davis,et al.  Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability‐enhancing activities , 1994, Clinical and experimental immunology.

[39]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[40]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[41]  J. A. Grant,et al.  Hereditary angioedema: its diagnostic and management perspectives. , 1990, The American journal of medicine.

[42]  R. Patterson,et al.  Idiopathic anaphylaxis: classification, evaluation, and treatment of 123 patients. , 1988, The Journal of allergy and clinical immunology.

[43]  M. Frank,et al.  Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. , 1988, The Journal of allergy and clinical immunology.

[44]  J. Alsenz,et al.  Autoantibody-mediated acquired deficiency of C1 inhibitor. , 1987, The New England journal of medicine.

[45]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[46]  M. Kerr,et al.  Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency. , 1985, Immunology.

[47]  A. Sheffer,et al.  Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. , 1985, The New England journal of medicine.

[48]  A. Kaplan,et al.  Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.

[49]  J. Dunn,et al.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. , 1983, The Journal of clinical investigation.

[50]  M. Cicardi,et al.  C1-inhibitor concentrate for treatment of hereditary angioedema. , 1980, The New England journal of medicine.

[51]  Rosen Fs,et al.  Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. , 1977 .

[52]  P. Schur,et al.  Acquired C1 inhibitor deficiency in lymphosarcoma , 1972 .

[53]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1971, The Journal of experimental medicine.

[54]  F. Rosen,et al.  Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.

[55]  R. R. Evans,et al.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.

[56]  W. Osler.  HEREDITARY ANGIO‐NEUROTIC ŒDEMA , 1888 .

[57]  J. Milton.  On Giant Urticaria , 1876, Edinburgh Medical Journal.